PhRMA letter claims Israel is weak on protecting intellectual property rights

Share this article:
PhRMA claims that the nation of Israel’s protection of intellectual property ights weakened last year, according to a report from the Israeli business publication Globes. The report said that PhRMA recently fired off a letter to the Office of the US Trade Representative claiming that Israel has taken measures to protect local generic pharmaceuticals (i.e. Teva Pharmaceuticals) and weakened legislation protecting intellectual property rights. The PhRMA letter went on to say that Israeli law gives generic pharmaceutical companies a free hand to manufacture generic drugs in Israel for export, mostly to the US, and provides no protection for the intellectual property rights of ethical pharmaceutical companies.  A PhRMA spokesperson told Globes the trade group was not targeting Teva or any other specific company.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.